Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences, Inc. (RCUS) is a healthcare company (biotechnology) based in the United States. The share price is $16.45, down 2.43% on the day, which values the company at $2.37B. Price as of 17 Nov 2026, 17:28 UTC, from Yahoo Finance.

Key facts

Share price
$16.45−2.43% today
Market value
$2.37B
Funk Score
39/100
Against its own history
Below its usual priceusual price $22.81
200-week average
$17.737% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Arcus Biosciences, Inc. in more detail

RCUS trades at -5.3× next year's expected earnings, 23.7× sales. Measured against its own history, the price is 28% below what its usual multiples would imply ($22.81) — below its usual price. It sits 7% below its 200-week average of $17.73.

Over the last five fiscal years Arcus Biosciences, Inc. has compounded revenue 25.9% a year. Its Funk Score is 39 out of 100 (financial strength 2.5, profitability 0.3, growth 8.7, value 4.3, each out of 10).

In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Weak Piotroski score.

1 of the superinvestors tracked here hold RCUS, including Julian and Felix Baker (0.1% of the portfolio).

Superinvestors holding RCUS

1 of the investors tracked here report a position in their latest 13F filing.

Arcus Biosciences, Inc. (RCUS): questions and answers

What is Arcus Biosciences, Inc.'s market cap?

Arcus Biosciences, Inc. is valued at $2.37B at a share price of $16.45.

Is RCUS overvalued or undervalued?

Against its own history, RCUS is below its usual price: the price is 28% below the $22.81 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is RCUS above its 200-week moving average?

No. RCUS is 7.2% below its 200-week average of $17.73. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Arcus Biosciences, Inc. growing?

Over the last five fiscal years Arcus Biosciences, Inc.'s revenue grew 25.9% a year.

Does RCUS pay a dividend?

Arcus Biosciences, Inc. does not currently pay a regular dividend.

Which famous investors own RCUS?

In their latest quarterly filings, Julian and Felix Baker (0.1% of the portfolio) hold RCUS. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Arcus Biosciences, Inc. (RCUS) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/RCUS

Underlying data: Yahoo Finance; company filings with the SEC.